Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH32364 in Locally Advanced or Metastatic Solid Tumors
NCT06975410Phase 2Recruiting
- Sponsor
- Yuhan
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ABL104 in solid tumor, sponsored by Yuhan. Started Jun 2025; status: recruiting.
02
Drugs
ABL104
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06975410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975410.